163 related articles for article (PubMed ID: 17132715)
1. Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia.
Deng R; Balthasar JP
Blood; 2007 Mar; 109(6):2470-6. PubMed ID: 17132715
[TBL] [Abstract][Full Text] [Related]
2. Amelioration of murine passive immune thrombocytopenia by IVIg and a therapeutic monoclonal CD44 antibody does not require the Myd88 signaling pathway.
Crow AR; Yu H; Han D; Lazarus AH
PLoS One; 2013; 8(8):e71882. PubMed ID: 23940791
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG.
Song S; Crow AR; Freedman J; Lazarus AH
Blood; 2003 May; 101(9):3708-13. PubMed ID: 12506021
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopenia.
Jin F; Tayab ZR; Balthasar JP
AAPS J; 2006 Jan; 7(4):E895-902. PubMed ID: 16594642
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic/pharmacodynamic modeling of IVIG effects in a murine model of immune thrombocytopenia.
Deng R; Balthasar JP
J Pharm Sci; 2007 Jun; 96(6):1625-37. PubMed ID: 17238194
[TBL] [Abstract][Full Text] [Related]
6. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia.
Hansen RJ; Balthasar JP
Blood; 2002 Sep; 100(6):2087-93. PubMed ID: 12200371
[TBL] [Abstract][Full Text] [Related]
7. CD44 antibody-mediated amelioration of murine immune thrombocytopenia (ITP): mouse background determines the effect of FcγRIIb genetic disruption.
Crow AR; Amash A; Lazarus AH
Transfusion; 2015 Jun; 55(6 Pt 2):1492-500. PubMed ID: 25496771
[TBL] [Abstract][Full Text] [Related]
8. Picogram doses of lipopolysaccharide exacerbate antibody-mediated thrombocytopenia and reduce the therapeutic efficacy of intravenous immunoglobulin in mice.
Tremblay T; Aubin E; Lemieux R; Bazin R
Br J Haematol; 2007 Oct; 139(2):297-302. PubMed ID: 17897306
[TBL] [Abstract][Full Text] [Related]
9. Investigation of antibody-coated liposomes as a new treatment for immune thrombocytopenia.
Deng R; Balthasar JP
Int J Pharm; 2005 Nov; 304(1-2):51-62. PubMed ID: 16171959
[TBL] [Abstract][Full Text] [Related]
10. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity.
Crow AR; Song S; Semple JW; Freedman J; Lazarus AH
Br J Haematol; 2001 Dec; 115(3):679-86. PubMed ID: 11736954
[TBL] [Abstract][Full Text] [Related]
11. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies.
Webster ML; Sayeh E; Crow M; Chen P; Nieswandt B; Freedman J; Ni H
Blood; 2006 Aug; 108(3):943-6. PubMed ID: 16861348
[TBL] [Abstract][Full Text] [Related]
12. Absence of cytokine modulation following therapeutic infusion of intravenous immunoglobulin or anti-red blood cell antibodies in a mouse model of immune thrombocytopenic purpura.
Aubin E; Lemieux R; Bazin R
Br J Haematol; 2007 Mar; 136(6):837-43. PubMed ID: 17341270
[TBL] [Abstract][Full Text] [Related]
13. Antibody specific for the glycophorin A complex mediates intravenous immune globulin-resistant anemia in a murine model.
Chen X; Ghaffar H; Jen CC; Lazarus AH
Transfusion; 2014 Mar; 54(3):655-64. PubMed ID: 23782137
[TBL] [Abstract][Full Text] [Related]
14. A monoclonal antibody with anti-D-like activity in murine immune thrombocytopenia requires Fc domain function for immune thrombocytopenia ameliorative effects.
Yu X; Menard M; Seabright G; Crispin M; Lazarus AH
Transfusion; 2015 Jun; 55(6 Pt 2):1501-11. PubMed ID: 25752470
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg.
Song S; Crow AR; Siragam V; Freedman J; Lazarus AH
Blood; 2005 Feb; 105(4):1546-8. PubMed ID: 15479722
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia.
Hansen RJ; Balthasar JP
J Pharm Sci; 2003 Jun; 92(6):1206-15. PubMed ID: 12761810
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin G dimers and immune complexes are dispensable for the therapeutic efficacy of intravenous immune globulin in murine immune thrombocytopenia.
Tremblay T; Paré I; Bazin R
Transfusion; 2013 Feb; 53(2):261-9. PubMed ID: 22670706
[TBL] [Abstract][Full Text] [Related]
18. Antagonism of the Platelet-Activating Factor Pathway Mitigates Inflammatory Adverse Events Driven by Anti-erythrocyte Antibody Therapy in Mice.
Won KD; Gil Gonzalez L; Cruz-Leal Y; Pavon Oro A; Lazarus AH
J Immunol; 2024 May; 212(10):1531-1539. PubMed ID: 38506555
[TBL] [Abstract][Full Text] [Related]
19. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?
Siragam V; Brinc D; Crow AR; Song S; Freedman J; Lazarus AH
J Clin Invest; 2005 Jan; 115(1):155-60. PubMed ID: 15630455
[TBL] [Abstract][Full Text] [Related]
20. Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody.
Bazin R; Lemieux R; Tremblay T
Br J Haematol; 2006 Oct; 135(1):97-100. PubMed ID: 16925577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
